Followers | 15 |
Posts | 571 |
Boards Moderated | 1 |
Alias Born | 08/04/2011 |
Tuesday, July 25, 2017 1:50:21 PM
Excerpt from May conference call. Of course listen to/read safe harbor statements preceding all CC's.
Unidentified Analyst
Okay, Mark, can you discuss the competition out there and with regard to that, what kind of patent protection do you have? Maybe discuss the strongest patents that you think you have and what kind of expiration dates these patents have? I mean, you have been doing this for a while, and ultimately someone, Dyadic or somebody else is going to want to – if this is successful proof of concept, is going to want to take this to the next step and start trials and go to the FDA and all that stuff takes a lot of time. So I’m just wondering what kind of patent protection you have and what kind of competitions is out there?
Mark Emalfarb
Yes, the competition, let’s address it first. A lot of competition in bacteria, yeast, CHO cells, so different levels of competition. Certain cell lines like bacteria can’t make glycoproteins at least naturally, so there is a variety of other expression systems out there. We did believe that C1 has the attributes and the properties that puts it to the top of the class and gives people the confidence that with the synthetic biology and the genomics and OMICS or the other tools that are out there today and getting better, quicker, faster and cheaper, it can be applied as cell line, that’s been proven industrially to be productive, robust and versatile and scalable, and this is the cell line you want to work with to get to the future.
(Cho cells from Chinese Hamster Ovaries are used in some of the best selling monoclonal antibodies such as Rituxan, Humira and Enbrel)
Recent DYAI News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2024 09:02:18 PM
- Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference • GlobeNewswire Inc. • 09/23/2024 01:50:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:15:54 PM
- Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 07/30/2024 08:00:00 PM
- Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership • GlobeNewswire Inc. • 06/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 01:26:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:31:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 09:36:45 PM
- Dyadic to Attend Industry Events in June • GlobeNewswire Inc. • 05/30/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 07:42:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:47:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:47:30 PM
- Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/14/2024 08:00:00 PM
- Dyadic to Attend Industry and Investor Events in May • GlobeNewswire Inc. • 05/08/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/08/2024 04:15:21 AM
- Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:30:00 PM
- Dyadic Reports 2023 Full Year Results and Recent Company Progress • GlobeNewswire Inc. • 03/28/2024 08:00:00 PM
- Dyadic Announces Change in Board and Management Leadership Roles • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- Dyadic to Attend Industry Events in April • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications • GlobeNewswire Inc. • 03/26/2024 12:30:00 PM
- Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024 • GlobeNewswire Inc. • 03/14/2024 08:30:00 PM
- CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization • GlobeNewswire Inc. • 03/11/2024 01:57:14 PM
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM